WO2012147092A2 - Novel salts of dpp-iv inhibitor - Google Patents
Novel salts of dpp-iv inhibitor Download PDFInfo
- Publication number
- WO2012147092A2 WO2012147092A2 PCT/IN2012/000148 IN2012000148W WO2012147092A2 WO 2012147092 A2 WO2012147092 A2 WO 2012147092A2 IN 2012000148 W IN2012000148 W IN 2012000148W WO 2012147092 A2 WO2012147092 A2 WO 2012147092A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pyrazin
- oxo
- butan
- triazolo
- dihydro
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention discloses certain new salts of (2R)-4-oxo-4-[3- (trifluoromethyl)-5,6-dihydro[ 1 ,2,4]-triazolo[4,3-a]pyrazin-7(8H)-yl]- 1 -(2,4,5- trifluorophenyl)butan-2-amine as well as their processes of preparation.
- the present invention also discloses certain novel crystalline forms of (2R)-4- oxo-4-[3-(trifluoromethyl)-5,6-dihydro[ l ,2,4]-triazoIo[4,3-a]pyrazin-7(8H)-yl]- l -
- the invention is related to novel salts and certain novel crystalline and amorphous forms of (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[ l ,2,4]-triazolo[4,3- a]pyrazin-7(8H)-yl]- l -(2,4,5-trifluorophenyl)butan-2-am ine salts.
- WO 03/004498 and US patent No. 6,699,871 both assigned to Merck and Co. describes a class of beta-amino tetrahydrotriazolo[4,3-a]pyrazines, which are inhibitors of DPP-IV. Disclosed therein are compounds, whose general formula is,
- WO 03/004498 is (2R)-4-oxo-4-[3-(trifluoromethyl)-5, 6-dihydro [ I ,2,4]-triazolo[4,3-a]pyrazin-7(8H)-yl]- l -(2,4,5-trifluorophenyl)butan-2- amine.
- WO 03/004498 is silent as to the preparation of and the nature of specific crystal forms of the salts.
- WO 2005/00313 describes dihydrogenphosphate salt of (2R)-4- oxo-4-[3-(trifluoromethyl)-5,6-dihydro[ l ,2,4]-triazolo[4,3-a]pyrazin-7(8H)-yl]-l - (2,4,5-trifluorophenyl)butan-2-amine and crystalline hydrates thereof, in particular a crystalline monohydrate.
- WO2005/020920 describes the crystalline anhydrate Form I, Form II and Form III as well as solvates of the (2R)-4- oxo-4-[3-(trifluoromethyl)-5.6-dihydro[ l ,2,4]-triazolo[4,3-a]pyrazin-7(8H)-yI]- l - (2,4,5-trifluorophenyl)butan-2-amine dihydrogenphosphate salt.
- WO2006/033848 describes the amorphous form of (2R)-4-oxo-4-[3- (trifluoromethyl)-5,6-dihydro[ l ,2,4]-triazolo[4,3-a]pyrazin-7(8H) yl]- l -(2,4,5- trifluorophenyl)butan-2-amine dihydrogenphosphate salt.
- WO2005/072530 describes crystalline hydrochloric acid, benzenesulfonic acid, p- toluenesu!fonic acid, 10-camphorsulfonic acid, and tartaric acid salts of (2R)-4-oxo- 4-[3-(trifluoromethyl)-5,6-dihydro[ l , 2,4]-triazolo[4,3-a]pyrazin-7(8H)-yl]- l -(2,4,5- trifluorophenyl)butan-2 -amine and hydrates thereof.
- WO2007/035198 describes (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6- dihydro[ 1 ,2,4]-triazolo[4,3-a]pyrazin-7(8H)-yl]- 1 -(2,4,5-trifluorophenyl)butan-2-amine dodecylsulfate salt, in particular, a crystalline anhydrate form thereof.
- Patent Publ ication No. WO 2010/00469 describes different crystalline form of salts of (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[ l ,2,4]-triazolo[4,3-a]pyrazin- 7(8H)-yl]- l -(2,4,5-trifluorophenyl)butan-2-amine such as hydrochloride, succinate, lactate, maleate, citrate and mesylate.
- WO 2010/092090 describes other acid addition salts of (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[ l ,2,4]-triazolo[4,3- a]pyrazin-7(8H)-yl]- l -(2,4,5-trifluorophenyl)butan-2-amine, i.e. salts of D-glucuronic acid, L-glucuronic acid, glutaric acid, lactic acid, L-mandelic acid, D-mandelic acid and sulfuric acid.
- the present invention satisfies this need by providing new salts of (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6- dihydro[ l ,2,4]-triazolo[4,3-a]pyrazin-7(8H)-yl]- l -(2,4,5-trifluorophenyl)butan-2- amine. !
- salts and new crystalline salt forms can show certain superior pharmaceutical properties compared to (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6- dihydro[ 1 ,2,4]-triazoIo[4,3-a]pyrazin-7(8H)-yl]- 1 -(2,4,5-trifluorophenyl)butan-2- amine.
- All of these salts may be present either in substantially crystalline or amorphous forms or may be present as partially crystalline forms.
- the present invention provide new salts and new crystalline salt forms of (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[ l ,2,4]-triazolo[4,3- a]pyrazin-7(8H)-yl]- l -(2,4,5-trifluorophenyl)butan-2-amine which can be used as an intermediate to prepare pure (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[l ,2,4]- triazolo[4,3-a]pyrazin-7(8H)-yl]- l -(2,4,5-trifluorophenyl)butan-2-amine and/or pure (2R)-4-oxo-4-[3-(trifluorome'thyl)-5,6-dihydro[ l ,2,4]-triazolo[4,3-a]pyrazin-7(8H)-yl
- new salts and new crystalline salt forms of (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[ 1 ,2,4]- triazolo[4,3-a]pyrazin-7(8H)-yl]- l -(2,4,5-trifluorophenyl)butan-2-am ine have desired physicochemical properties such as improved stability and/or solubility.
- This compound also shows superior efficacy over the (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6j- dihydro[ l ,2,4]-triazolo[4,3-a]pyrazin-7(8H)-yl]- l -(2,4,5-trifluorophenyl)butan-2-amine from which it is derived.
- FIG. 1 is a powder X-ray diffraction (XRPD) pattern of crystalline gentisate salt of 2(R) 4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[ 1 ,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]- l -(2!4,5-trifluorophenyl)butan-2-amine according to the present invention.
- XRPD powder X-ray diffraction
- FIG. 2 is a powder X-ray diffraction (XRPD) pattern of amorphous gentisate salt of
- FIG. 3 is a powder X-ray diffraction (XRPD) pattern of crystall ine adipate salt of 2(R) 4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[ I ,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-l - (2,4,5-trifluorophenyl)butan-2-amine according to the present invention.
- XRPD powder X-ray diffraction
- FIG. 4 is a powder X-ray diffraction (XRPD) pattern of crystalline hydrochloride salt of 2(R) 4-oxo-4-[3-(frifluoromethyl)-5,6-dihydro[l ,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]j- l -(2,4,5-trifluorophenyl)butan-2-amine according to the present invention.
- XRPD powder X-ray diffraction
- FIG. 6 is a powder X-ray diffraction (XRPD) pattern of crystalline trifluoroacetic acid salt of (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[l ,2,4]triazolo[4,3-a]pyrazin- 7(8H)-yl]- l -(2,4,5-trifluorophenyl)butan-2-amine according to the present invention.
- XRPD powder X-ray diffraction
- FIG. 8 is a powder X-ray diffraction (XRPD) pattern of amorphous besylate salt of 2(R) 4-oxo-4-[3-(trifIuoromethyl)-5,6-dihydro[ l ,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]- 1 -(2,4,5-trifluorophenyl)butan-2-amine according to the present invention.
- XRPD powder X-ray diffraction
- FIG. 9 Effect of single dose oral administration of ZY compounds at 10 mg/kg, PO on OGTT in male C57 mice.
- FIG. 10- Effect of single dose oral administration of ZY compounds at l Omg/kg, PO on OGTT in male C57 mice.
- the present invention provides gentisate salt of (2R)-4-oxo-4- [3-(trifluoromethyl)-5,6-dihydro[ 1 ,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]- 1 -(2,4,5- trifluorophenyI)butan-2 -amine and processes for their preparation.
- the present invention provides a crystalline form of gentisate salt of (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[ l ,2,4]triazolo[4,3- a]pyrazin-7(8H)-yl]- l -(2,4,5-trifluorophenyl)butan-2-amine, which can be characterized by its powder X-ray diffraction (PXRD) pattern and other characteristic properties as described hereinafter and process of preparation thereof.
- PXRD powder X-ray diffraction
- the present invention provides the amorphous form of the gentisate salt of 4-oxo-4-[3-(trifluoromethyl)-5,6- dihydro[ l ,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-l -(2,4,5-trifluorophenyl)butan-2 -amine, which can be characterized by its powder X-ray diffraction (PXRD) pattern and other characteristic properties as described hereinafter and process for preparation thereof.
- PXRD powder X-ray diffraction
- the present invention provides an adipate salt of (2R)-4-oxo- 4-[3-(trifluoromethyl)-5,6-dihydro[ l ,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]- l -(2,4,5- trifluorophenyl)butan-2-amine and processes for their preparation.
- the present invention provides a novel trifluoroacetic acid salt of (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[ l ,2,4]triazolo[4,3-a]pyrazin- 7(8H)-yl]- l -(2,4,5-trifluoropheiiyl)butan-2-amine and processes for its preparation.
- the present invention provides a new crystalline form of the hydrochloride salt of (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[ l ,2,4]triazolo[4,3- a]pyrazin-7(8H)-yl]- l -(2,4,5-trifluoiOphenyl)butan-2-amine, which can be characterized by its powder X-ray diffraction (PXRD) pattern and other characteristic properties as described hereinafter and process for preparation thereof.
- PXRD powder X-ray diffraction
- the present invention provides a new crystalline besylate salt(I) of (2R)-4-oxd-4-[3-(trifIuoromethyl)-5,6-dihydro[ I ,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]- l -(2,4,5-trifluorophenyl)butan-2-amine, which can be characterized by its powder X- ray diffraction (PXRD) pattern and other characteristic properties as, described hereinafter and process for preparation thereof.
- PXRD powder X- ray diffraction
- the present invention provides a new crystal line besylate salt(II) of (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[l ,2,4]triazolo[4,3-a]pyrazin- 7(8H)-yl]- l -(2,4,5-trifluorophenyl)butan-2-amine, which can be characterized by its powder X-ray diffraction (PXRD) pattern and other characteristic properties as described hereinafter and process for preparation thereof.
- PXRD powder X-ray diffraction
- the present invention provides an amorphous form of besylate salt of (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1 ,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]- l -(2,4,5-trifluorophenyl)butan-2-amine, which can be characterized by its powder X- i ray diffraction (PXRD) pattern and other characteristic properties as described hereinafter and process for preparation thereof.
- PXRD powder X- i ray diffraction
- distillation temperature refers to the boiling point of the solvent used.
- PXRD powder X-ray diffraction
- (2R)-4-oxo-4-[3-(trifluoiOmethyl)-5,6- dihydro[ l ,2,4]-triazolo[4,3-a]pyrazin-7(8H)-yl]- l -(2,4,5-trif1uorophenyl)butan-2-amine refers to Sitagliptin.
- THF tetrahydrofuran
- DCM dichloro methane
- DIPE di-isopropyl ether
- MTBE methyl t-butyl ether
- I PA isopropyl alcohol
- IPAc isopropyl acetatel
- phosphate refers to dihydrogen phosphate salt
- besylate refers to benzenesulphonic acid salt
- (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[ l ,2,4]-triazolo[4,3-a]pyrazin-7(8H)-yl]- l -(2,4,5-trifluorophenyl)butan-2-amine is having structural formula (1).
- the invention discloses novel gentisate salt of (2R)-4- oxo-4-[3-(trifluoromethyl)-5,6-dihydro[ l ,2,4]-triazolo[4,3-a]pyrazin-7(8H)-yl]- l - (2,4,5-trifluorophenyl)butan-2-amine.
- this salt may be present either in crystalline or amorphous form or suitable mixtures of crystalline and amorphous forms.
- the crystalline and/or amorphous forms may exist either in hydrated, solvated as well as non-sol vated forms.
- the invention provides a process for the synthesis of gentisate salt of (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[ 1 ,2,4]-triazolo[4,3-a]pyrazin- 7(8H)-yl]- 1 -(2,4, 5-trifluorophenyl)butari-2-amine which comprises
- the suitable solvents used may be selected from alcohols such as methanol, ethanol, isopropanol, butanol, 1 ,2-dimethoxy ethanol, 2-methoxy ethanol, 2-ethoxy ethanol, ethylene glycol and the like, water and suitable mixtures of one or more of the solvents described above.
- the (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6- dihydro[l ,2,4]-triazolo[4,3-a]pyrazin-7(8H)-yl]-l -(2,4,5-trifluorophenyl)butan-2-amine gentisic acid salt of the present invention can be prepared by reacting a (2R)-4-oxo-4- [3-(trifluoromethyl)-5,6-dihydro[ l ,2,4]-triazolo[4,3-a]pyrazin-7(8H)-yl]- I -(2 l ,4,5- trifluorophenyl)butan-2-amine salt of a first acid with a gentisic acid, provided that the gentisic acid is stronger and sets free the first, weaker acid.
- Another aspect, of the present invention provides for the new gentisate salt of (2R) 4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[ 1 ,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]- l -(2,4,5-trifluorophenyl)butan-2-amine in a crystalline form.
- the crystalline form is further characterized by an additional XPRD peaks at about 6.53, 1 8.02, 19.68, 20.32, 23.40, 24.73, 27.05, 27.68, 29.38° ⁇ 0.2° degrees 2 ⁇ .
- Fig. l il lustrate the XRD of the crystalline form of 4-oxo-4-[3-(trifluoromethyl)-5,6- dihydro[l ,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]- l -(2,4,5-trifluorophenyl)butan-2-amine gentjsate salt.
- the invention provides a process for the synthesis of crystalline (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[ l ,2,4]-triazolo[4,3-a]pyrazin- 7(8H)-yl]- l -(2,4,5-trifluorophenyI)butan-2-amine gentisate salt, said process comprising crystallization of (2R) 4-oxo-4-[3-(trifluoromethyl)-5,6- dihydro[ l ,2.4]triazolo[4,3-a]pyrazin-7(8H)-yl]- l -(2,4,5-trifluorophenyl)butan-2-amine gentisate salt in the presence of suitable solvent and optionally further adding suitable anti solvents and subsequently removing the solvent, when necessary.
- the suitable solvents used may be selected from alcohols such as methanol, ethanol, isopropanol, butanol, 1 ,2-dimethoxy ethanol, 2-methoxy ethanol, 2-ethoxy ethanol, ethylene glycol and the like; hydrocarbons such as hexane, heptanes, cyclohexane, toluene, xylene, chlorobenzene and the like and suitable mixtures of one or more of the solvents described above. Preferably a mixture of alcohol and hydrocarbon.
- Another aspect of the present invention includes the new gentisate salt of (2 ) 4-oxo-4j- [3-(trifluoromethyl)-5,6-dihydro[ l ,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]- l -(2,4,5- trif!uorophenyl)butan-2-amine in amorphous form.
- Fig.2 illustrate the
- the invention provides a process for the synthesis of the amorphous form of (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[ l ,2,4]-triazolo[4,3- a]pyrazin-7(8H)-yl]- l -(2,4,5-trifluorophenyl)butan-2-amine gentisate salt, said process comprising reaction of the free base with the gentisic acid in suitable solvent under suitable conditions and optionally adding suitable anti solvents and removing the solvent when necessary.
- the suitable solvents used may be selected from alcohols such as methanol, ethanol, isopropanol, butanol, 1 ,2-dimethoxy ethanol, 2-methoxy ethanol 1 , 2-ethoxy ethanol, ethylene glycol and the like and water and suitable mixtures of one or more of the solvents described above to prepare gentisate salt.
- the invention provides a process for the synthesis of amorphous (2R)-4-0xo-4-[3-(trifluoromethyl)-5,6-dihydro l ,2,4]-triazolo[4,3- a]pyrazin-7(8H)-yl]- l -(2,4,5-trifluorophenyl)butan-2-amine gentisate salt, said process comprising dissolving or slurring of (2R) 4-oxo-4-[3-(trifluoromethyl)-5,6- dihydro[ l ,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]- l -(2,4,5-trifluorophenyl)butan-2-amine gentisate salt in the presence of suitable solvent and optionally further adding suitable anti solvents and subsequently removing the solvent, when necessary.
- the suitable solvents used may be selected from alcohols such as methanol, ethanol, isopropanol, butanol, 1 ,2-dimethoxy ethanol, 2-methoxy ethanol, 2-ethoxy ethanol, ethylene glycol and the like; esters such as ethyl acetate, isopropyl acetate and the like; chlorinated solvents such as chloroform, dichloromethane and the like; nitriies such as acetonitrile and the like; ethers such as diethyl ether, 1 ,4-dioxane, DIPE, MTBE, THF and the like and suitable mixtures of one or more of the solvents described above.
- alcohols such as methanol, ethanol, isopropanol, butanol, 1 ,2-dimethoxy ethanol, 2-methoxy ethanol, 2-ethoxy ethanol, ethylene glycol and the like
- esters such as ethyl acetate, isopropy
- the invention discloses novel adipate salt of (2R)-4-oxo-4-[3- (trifluoromethy l)-5,6-dihydro[ 1 ,2,4]-triazolo[4,3-a]pyrazin-7(8H)-yl]- l -(2,4,5- trifluorophenyl)butan-2-amine.
- this salt may be present either in crystalline or amorphous form or suitable mixtures of crystalline and amorphous forms.
- the crystalline and/or amorphous forms may exist either in hydrated, solvated as well as non-solvated forms.
- the invention provides a process for the synthesis of the adipate salt of (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[ l ,2,4]-triazolo[4,3'- a]pyrazin-7(8H)-yl]- l -(2,4,5-trifluorophenyl)butan-2-amine.
- Adipate salts may be prepared by reaction of the free base (formula I) under suitable reaction conditions with the adipic acid in water or one or more suitable organic solvents or in a mixture of water and one or more suitable organic solvents and removing the solvent when necessary.
- the suitable solvents used may be selected from alcohols such as methanol, ethanol, isopropanol, butanol, 1 ,2-dimethoxy ethanol, 2-methoxy ethanol, 2-ethoxy ethanol, ethylene glycol and tjhe like and suitable mixtures thereof.
- the (2R)-4-oxo-4-[3-(trifluoiOmethyl)-5,6-dihydro[ 1 ,2,4]- triazolo[4,3-a]pyrazin-7(8H)-yl]- l -(2,4,5-trifluorophenyl)butan-2-amine adipate salts of the present invention can be prepared by reacting a (2R)-4-oxo-4-[3-(trifluoromethyl)- 5,6-dihydro[ 1 ,2,4]-triazolo[4,3-a]pyrazin-7(8H)-y I]- 1 -(2,4,5-trifluoropheny l)butan-2- amine salt of a first acid with adipic acid, provided that the adipic acid is stronger and sets free the first, weaker acid.
- the crystalline form is further characterized by an additional XPRD peaks at about 5.98, 10.03, 13.78, 15.72, 16.15, 22.34, 22.85, 25.09, 25.45 and 29.43 ° ⁇ 0.2° degrees 2 ⁇ .
- Fig.3 illustrate the XRD of a crystalline form of 4-oxo-4-[3-(trifluoromethyl)- 5,6-dihydro[ 1 ,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-l -(2,4,5-trifluorophenyl)butan-2- amine adipate salt.
- the invention discloses novel trifluoro aceticacid salt of (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[ l ,2,4]-triazolo[4,3-a]pyrazin-
- this salt may be present either in crystalline or amorphous form or suitable mixtures of crystalline and amorphous forms.
- the crystalline and/or amorphous forms may exist either in hydrated, solvated as well as non-solvated forms.
- the invention provides a process for the synthesis of trifluoro aceticacid salt of (2R)-4-oxo-4-[3-(trifluoromethyl)-5, 6-dihydro[ 1 ,2,4]- triazolo[4,3-a]pyrazin-7(8H)-yl]-l -(2,4,5-trifluorophenyl)butan-2-amine.
- Trifluoro aceticacid salts can be prepared by reaction of the free base (formula I) under suitable reaction conditions with the trifluoro aceticacid in water or one or more suitable organic solvents or in a mixture of water and one or more suitable organic solvents or mixture of suitable solvents and subsequently removing water or the solvent used, under suitable conditions when necessary.
- the suitable solvents used may be selected from alcohols such as methanol, ethanol, isopropanol, butanol, 1 ,2-dimethoxy ethanol, 2-methoxy ethanol, 2-ethoxy ethanol, ethylene glycol and the like and suitable mixtures of one or more of the solvents described above.
- the (2R)-4-oxo-4-[3- (trifluoromethyl)-5,6-dihydro[ l ,2,4]-triazolo[4,3-a]pyrazin-7(8H)-yl]-l -(2,4,5- trifluorophenyl)butan-2 -amine trifluoro aceticacid salt of the present invention can be prepared by reacting a (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[ l ,2,4]- triazolo[4,3-a]pyrazin-7(8H)-yl]- l -(2,4,5-trifluorophenyl)butan-2-amine salt of a first acid with a trifluoro aceticacid, provided that the trifluoro aceticacid is stronger and sets free the first, weaker acid.
- Suitable weaker acid salt of first acid is selected from HC1, acetic acid.
- Another aspect of the present invention provides for the new trifluoroacetic acid salt of (2R) 4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[ l ,2;4]triazolo[4,3-a]pyrazin- 7(8H)-yl]- 1 -(2,4,5-trifluorophenyl)butan-2-amine in a crystalline form.
- the crystal line form of (2R) 4-oxo-4-[3-(trifluoromethyl)-5,6- dihydro[ 1 ,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]- 1 -(2,4,5-trifluorophenyl)butan-2-amine trifluoroacetic acid salt have a characteristic XRD peaks at about 6.64, 9.39, 10.99, 13.40, 15.32, 1 7. 15, 19.20, 1 9.66, 21 .48, 22.46, 24.68, 26.89, 27.86, 29.34, 3 1 .24, 32.77 and 34.82 0 ⁇ 0.2 degrees 2 ⁇ .
- Fig.6 illustrate the XRD of crystalline form of 4-oxo-4-[3-(trifluoromethyl)-5,6- dihydro[ l ,2,4]triazolo[4.3-a]pyrazin-7(8H)-yl]- l -(2,4,5-trifluorophenyl)butan-2-amine trifluoroacetic acid salt.
- Another aspect of the invention relates to a process for the preparation of crystalline form of (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[ l ,2,4]-triazolo[4,3- a]pyrazin-7(8H)-yl]- l -(2,4,5-trifluorophenyl)butan-2-amine trifluoroacetic acid salt, said process comprising crystallization of (2R) 4-oxo-4-[3-(trifluoromethyl)-5,6- dihydro[ l ,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]- l -(2,4,5-trifluorophenyl)butan-2-amine trifluoro acetic acid salt in the presence of suitable solvent and optionally further adding suitable anti solvents and subsequently removing the solvent, when necessary.
- the suitable solvents used may be selected from alcohols such as methanol, ethanol, isoprppanol, butanol, 1 ,2-dimethoxy ethanol, 2-methoxy ethanol, 2-ethoxy ethanol, ethylene glycol and the like; festers such as ethyl acetate, isopropyl acetate and the like; ethers such as diethyl ether, 1 ,4-dioxane, DIPE, MTBE, THF and the like and suitable mixtures of one or more of the solvents described above.
- alcohols such as methanol, ethanol, isoprppanol, butanol, 1 ,2-dimethoxy ethanol, 2-methoxy ethanol, 2-ethoxy ethanol, ethylene glycol and the like
- festers such as ethyl acetate, isopropyl acetate and the like
- ethers such as diethyl ether, 1 ,4-dioxane,
- Another aspect of the invention relates to a process for the preparation of a new crystalline hydrochloride salt of (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[l ,2,4]L triazolo[4,3-a]pyrazin-7(8H)-yl]- l -(2,4,5-trifluorophenyl)butan-2-amine.
- a new crystalline hydrochloride salt can be prepared by reaction of the free base (formula I) under suitabjle reaction conditions with the hydrochloric acid in water or one or more suitable organic solvents or in a mixture of waterand one or more suitable organic solvents and removing the solvent under suitable conditions when necessary.
- the suitable solvents used may be selected from alcohols such as methanol, ethanol, isopropanol, butanol, 1 ,2-dimethoxy ethanol, 2-methoxy ethanol, 2-ethoxy ethanol, ethylene glycol, hexanol, heptanol, octanol, decanol and the like; ethers such as diethyl ether, 1 ,4-dioxane, DIPE, MTBE, THF and the like and suitable mixtures of one or more of the solvents, described above.
- alcohols such as methanol, ethanol, isopropanol, butanol, 1 ,2-dimethoxy ethanol, 2-methoxy ethanol, 2-ethoxy ethanol, ethylene glycol, hexanol, heptanol, octanol, decanol and the like
- ethers such as diethyl ether, 1 ,4-dioxane,
- the crystalline form is further characterized by an additional XPRD peaks at about 16.03, 1 8.71 , 22.36. 24 ⁇ .79, 26.49 + 0.2° degrees 2 ⁇ .
- Fig.4 illustrate the XRD of crystalline form of (2R)-4-oxo-4-[3-
- the invention discloses a novel crystalline form of besylate salt(I) of (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[ l ,2,4]-triazo.lo[4,3f- a]pyrazin-7(8H)-yl]- l -(2,4,5-trifluorophenyl)butan-2-amine.
- Another aspect of the invention relates to a process for the preparation of a novel crystalline form of besylate salt(I) of (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6- dihydro[ l ,2,4]-triazolo[4,3-a]pyrazin-7(8H)-yl]- l -(2,4,5-trifluorophenyl)biitan-2- amine.
- a novel crystalline form of besylate salt(I) can be prepared by reaction of the free base (formula 1) under suitable reaction conditions with the benzensulfonic acid in one dr more suitable organic solvents and removing the solvent when necessary.
- the suitable solvents used may be selected from esters such as ethyl acetate, isopropyl acetate and the like; hydrocarbons such as hexane, heptanes, cyclohexane, toluene, xylene, chlorobenzene and the like and suitable mixtures of one or more of the solvents described above.
- the crystall ine form is further characterized by an additional XPRD peaks at about 12.62, 1 7.05, 19.35, 22. 13, 27.56 ° ⁇ 0.2° degrees 2 ⁇ .
- I Fig.5 illustrate the XRD of crystalline form of 4-oxo-4-[3-(trifluoromethyl)-5,6- dihydro[ 1 ,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]- 1 -(2,4,5-trifluorophenyl)butan-2-amine besylate(I ) salt.
- Another aspect of the invention relates to a process for the preparation of a new crystalline form II of besylate salt(II) of (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6- dihydro[ l ,2,4]-triazolo[4,3-a]pyrazin-7(8H)-yl]- l -(2,4,5-trifIuorophenyl)butan-2- am ine.
- a new crystal line besylate salt(II) can be prepared by reaction of the free base under suitable reaction conditions with the benzenesulphonic acid in water or one or more suitable organic solvents or in a mixture of water and one or more suitable organic solvents or a suitable m ixture of one or more organic solvents and subsequently removing the solvent under suitable conditions as are well known, when necessary.
- the suitable solvents used may be selected from a m ixture of esters and water, m ixture of esters, ethers and
- the suitable alcohols used iis selected from methanol, ethanol, isopropanoi, butanol, 1 ,2-dimethoxy ethanol, 2-methoxy ethanol, 2-ethoxy ethanol, ethylene glycol, hexanol, heptanol, octanol, decanol and the l ike; esters used is selected from ethyl acetate, isopropyl acetate and the like; chlorinated solvents used is selected from chloroform, dichloromethane and the like; hydrocarbons used is selected from hexanJ, heptanes, cyclohexane, toluene, xylene, chlorobenzene and the l ike; ketones used is selected from acetone and the like; ethers used is selected from diethyl ether, 1 ,4- dioxane, DIPE, TBE, THF and the like.
- the crystal line form I I of (2R)-4-oxo-4-[3-(trifluororriethyl)-5,6- dihydi [ l ,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]- l -(2,4,5-trifluorophenyl)butan-2-am ine besylate salt have a characteristic XRD peaks at about 5.69, 7.45, 1 0.08, 1 1 .41 , 13.09, 1 8.34, 22.52 and 22.97 ° + 0.2 degrees 2 ⁇ .
- the crystalline form I I is further characterized by an additional XPRD peaks at about 1 6.63, 20.82, 2 1 .95, 23.75, 24.49, 25.02, 26.43, 27.66 and 30. 1 9 ⁇ 0.2° degrees 2 ⁇ .
- Fig.7 il lustrate the XRD of crystal l ine form I I of (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6- dihydro[ l ,2,4]triazolo[4,3-a] pyrazin-7(8H)-yl]- l -(2,4,5-trifluorophenyl)butah-2-amine besylate salt.
- the present invention further includes substantially aji amorphous form of besylate salt of (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6- dihydro[ l ,2,4]-triazolo[4,3-a]pyrazin-7(8H)-yl]- l -(2,4,5-trifluorophenyl)butan-2-amine and processes to prepare the same.
- Substantially amorphous besylate salt of (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6- dihydro[ l ,2,4]-triazolo[4,3-a]pyrazin-7(8H)-yl]- l -(2,4,5-trifluorophenyl)butan-2-amine in the present invention includes more than about 80%, more than about 90%, more than about 95%, or more than about 99%, by weight of amorphous content, the corresponding balance amount comprising of crystalline substances.
- the present invention provides processes for the preparation of amorphous besylate salt of (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[ 1 ,2,4]- triazolo[4,3-a]pyrazin-7(8H)-yl]- l -(2,4,5-trifluorophenyl)butan-2-amine, which comprises:
- the step a) may involve dissolving the active substance in a solvent that is suitable for easy, commercially viable solvent removal via distillation, etc.
- the solvent that can be used for preparing amorphous besylate salt of (2R)-4-oxo-4-[3 ! - (trifluoromethyl)-5,6-dihydro[ l ,2,4]-triazolo[4,3-a]pyrazin-7(8H)-yl]- l -(2,4,5- trifluorophenyl)butan-2-amine may be from the, various classes of solvents such as for example alcohols, halogenated hydrocarbons, water or mixtures of any two or more thereof.
- Alcohol solvents include for example methanol, ethanol, denatured spirits, n- propanol, isopropanol, n-butanol, isobutanol, and t- butanol and the like.
- Halogenated hydrocarbons include for example dichloromethane, 1 ,2-dichloroethane, chloroform, carbon tetrachloride and the like.
- organic solvent acceptable for the practice of the process described herein preferably provide sufficient solubility for the active substance, and do not cause any undesirable chemical reactions with the besylate salt of (2R)-4-oxo-4-[3-(trifluoromethyl)-5i6-dihydro[ l ,2,4]-triazolo[4,3-a]pyrazin-7(8H)-yl]- l -(2,4,5-trifluorophenyl)butan-2-amine, or (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6- dihydro[ l ,2,4]-triazolo[4,3-a]pyrazin-7(8H)-yl]- l -(2,4,5-trifluorophenyl)butan-2- amine, such as degradation or side reaction, under the conditions of processing.
- the recovering step b) may involve removing the solvent by distillation or by filteration.
- rapid drying is utilized to provide the amorphous form of besylate salt of (2R)-4-oxo-4-[3-(trifluoromethy l)-5,6-dihydro[ 1 ,2,4]- triazolo[4,3-a]pyrazin-7(8H)-yl]- l -(2,4,5-trifluorophenyl)butan-2-amine with desired stability, moisture content and residual solvent characteristics.
- the resultant product may be dried using any methods of drying including spray drying, rotational evaporation (such as using a Btichi Rotavapor), agitated thin film drying, spin-flash drying, fluid-bed drying, lyophilization, or other techniques known in the art.
- the process may also include further drying of the product obtained from the solution by vacuum drying over a 'desiccant, such as phosphorous pentoxide (P2O5).
- a 'desiccant such as phosphorous pentoxide (P2O5).
- P2O5 phosphorous pentoxide
- the product can also be obtained with other suitable drying agents such as potassium carbonate ( 2CO3), sodium carbonate (TMa2C03), silica gel and the like, as will be apparent to the skilled artisan.
- Fig. 8 illustrates the XRD of an amorphous form of (2R)-4-oxo-4-[3- (trifluoromethyl)-5,6-dihydro[ ] ,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1 -(2,4,5- trifluorophenyl)butan-2 -amine besylate salt.
- Scan mode Continuous, Scan speed : 4.000 Sampling width : 0.010°, Scan axes : 2 theta vs CPS, Scan range : 4° to 40.0°', Theta offset: 0.000.
- Sample Size Approx. l -2mg
- Sample Pans Hermetic/Crimping Pans
- novel gentisate and adipate salt of the present application have some pharmaceutical advantages over the free base in the preparation of pharmaceutical drug product because both the novel salts
- WO03004498 does not provide any biological activity data of the (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[ l ,2,4]triazolo[4,3-a]pyrazin- 7(8H)-yl]- l -(2,4,5-trifluorophenyl)butan-2-amine.
- ⁇ amine gentisate, the crystalline form II and amorphous forms of besylate salt of (2R)-4- oxo-4-[3-(trifluoromethyl)-5,6-dihydro[l ,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1 -(2,4,5- trifluorophenyl)butan-2-amine of the present invention is derived from (2R)-4-oxo-4- [3-(trifluoromethyl)-5,6-dihydro[ l ,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-l -
- mice Eight to ten weeks old male C57BL S/J mice obtained from Animal Research Facility of Zydus Research Centre were used. The mice were allowed ad libitum access to chow and water. Animals ,were on a 12-hour light, 12-hour dark cycle. Protocol for use of animals for conducting this study has been reviewed and approved by Institutional Animal Ethics Committee (IAEC).
- IAEC Institutional Animal Ethics Committee
- Oral glucose tolerance test was performed on these animals. The mice were deprived of food for 1 8 h and then drug or vehicles were administered with a glucose load (3 g/ kg) by oral route. Blood (200 ⁇ ) samples were collected at 0, 30, 60, 120 and 240 min. Serum glucose concentrations were determined using commercially available kits purchased from RFCL (New Delhi, India) using spectrophotometric assay. The glucose values were then analyzed using GraphPad Prism version 5.04 for Windows; GraphPad Software, San Diego, CA, USA. The area under the curve for 120 min was calculated, based on which the percentage inhibition was obtained for each treatment. Results:
- the gentisic acid salt of (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6- dihydro[l ,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]- l -(2,4,5-trifluorophenyl)butan-2-amine was formed by mixing gentisic acid (0.1 89 g) and (2R)-4-oxo-4-[3-(trifluoromethyl)- 5,6-dihydro[ 1 ,2,4]triazolo[4,3-a]pyrazin-7(8H)-yI]- 1 -(2,4,5-trifluorophenyl)butan-2- amine (0.500 g) in methanol (2.5 mL), followed by stirring at reflux temperature for 2 h. The solvent was disti lled out at reduced pressure to obtain solid gentisate salt (Wt.: 0.680 g)
- the gentisic acid salt of (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6- dihydro[ l ,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]- l -(2,4,5-trifluorophenyl)butan-2-amine was formed by mixing gentisic acid (0.1 13 g) , (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6- dihydro[ l ,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]- l -(2,4,5-trifluorophenyl)butan-2-amine (0.300 g) in a mixture of isopropylalcohol (0.6 mL) and acetonitrile ( 1 .5 mL), followed by stirring at reflux temperature for 2 h.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Description
Claims
Priority Applications (13)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/002,541 US9108972B2 (en) | 2011-03-03 | 2012-03-02 | Salts of DPP-IV inhibitor |
JP2013555995A JP2014510071A (en) | 2011-03-03 | 2012-03-02 | Novel salts of DPP-IV inhibitors |
ES12766329.2T ES2548269T3 (en) | 2011-03-03 | 2012-03-02 | New crystalline form of a DPP-IV inhibitor |
AU2012247127A AU2012247127B2 (en) | 2011-03-03 | 2012-03-02 | Novel salts of DPP-IV inhibitor |
AP2013007101A AP2013007101A0 (en) | 2011-03-03 | 2012-03-02 | Novel salts of DPP-IV inhibitor |
BR112013022504A BR112013022504A8 (en) | 2011-03-03 | 2012-03-02 | gentisate, adipate, trifluoroacetic acid salt, crystalline form of hydrochloride, crystalline form of besylate, amorphous besylate and processes for their preparation |
KR1020137026089A KR20130132631A (en) | 2011-03-03 | 2012-03-02 | Novel salts of dpp-iv inhibitor |
DK12766329.2T DK2681220T3 (en) | 2011-03-03 | 2012-03-02 | PRESENT UNKNOWN SALTS OF DPP-IV INHIBITOR |
SG2013064886A SG192973A1 (en) | 2011-03-03 | 2012-03-02 | Novel salts of dpp-iv inhibitor |
MX2013010027A MX2013010027A (en) | 2011-03-03 | 2012-03-02 | Novel salts of dpp-iv inhibitor. |
CN2012800168764A CN103476778A (en) | 2011-03-03 | 2012-03-02 | Novel salts of DPP-IV inhibitor |
EP12766329.2A EP2681220B1 (en) | 2011-03-03 | 2012-03-02 | Novel crystalline form of a dpp-iv inhibitor |
PH12015501536A PH12015501536A1 (en) | 2011-03-03 | 2015-07-08 | Novel salts of dpp-iv inhibitor |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN590MU2011 | 2011-03-03 | ||
IN590/MUM/2011 | 2011-03-03 | ||
IN1948MU2011 | 2011-07-06 | ||
IN1948/MUM/2011 | 2011-07-06 | ||
IN2777MU2011 | 2011-09-30 | ||
IN2777/MUM/2011 | 2011-09-30 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2012147092A2 true WO2012147092A2 (en) | 2012-11-01 |
WO2012147092A3 WO2012147092A3 (en) | 2013-03-14 |
Family
ID=54290089
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IN2012/000148 WO2012147092A2 (en) | 2011-03-03 | 2012-03-02 | Novel salts of dpp-iv inhibitor |
Country Status (13)
Country | Link |
---|---|
US (1) | US9108972B2 (en) |
EP (4) | EP2899194A1 (en) |
JP (1) | JP2014510071A (en) |
KR (1) | KR20130132631A (en) |
CN (2) | CN104788456A (en) |
AU (1) | AU2012247127B2 (en) |
BR (1) | BR112013022504A8 (en) |
DK (1) | DK2681220T3 (en) |
ES (1) | ES2548269T3 (en) |
MX (1) | MX2013010027A (en) |
PH (1) | PH12015501536A1 (en) |
SG (2) | SG10201405403QA (en) |
WO (1) | WO2012147092A2 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013084210A1 (en) * | 2011-12-08 | 2013-06-13 | Ranbaxy Laboratories Limited | Amorphous form of sitagliptin salts |
ES2690866A1 (en) * | 2016-12-08 | 2018-11-22 | Alparis, S.A. De C.V. | NEW SOLID FORMS OF SITAGLIPTINE (Machine-translation by Google Translate, not legally binding) |
WO2022058044A1 (en) | 2020-09-15 | 2022-03-24 | Pharmathen S.A. | Solid dosage form comprising sitagliptin and method of preparation thereof |
WO2022228735A1 (en) | 2021-04-27 | 2022-11-03 | Pharmathen S.A. | Pharmaceutical composition comprising a combination of sitagliptin and metformin and method of preparation thereof |
WO2023139276A1 (en) | 2022-01-24 | 2023-07-27 | Zaklady Farmaceutyczne Polpharma S.A. | Process for preparing crystalline sitagliptin hydrochloride monohydrate |
Citations (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003004498A1 (en) | 2001-07-06 | 2003-01-16 | Merck & Co., Inc. | Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
WO2005003135A1 (en) | 2003-06-24 | 2005-01-13 | Merck & Co., Inc. | Phosphoric acid salt of a dipeptidyl peptidase-iv inhibitor |
WO2005020920A2 (en) | 2003-09-02 | 2005-03-10 | Merck & Co., Inc. | Novel crystalline forms of a phosphoric acid salt of a dipeptidyl peptidase-iv inhibitor |
WO2005030127A2 (en) | 2003-09-23 | 2005-04-07 | Merck & Co., Inc. | Novel crystalline form of a phosphoric acid salt of a dipeptidyl peptidase-iv inhibitor |
WO2005072530A1 (en) | 2004-01-16 | 2005-08-11 | Merck & Co., Inc. | Novel crystalline salts of a dipeptidyl peptidase-iv inhibitor |
WO2006033848A1 (en) | 2004-09-15 | 2006-03-30 | Merck & Co., Inc. | Amorphous form of a phosphoric acid salt of a dipeptidyl peptidase-iv inhibitor |
WO2007035198A2 (en) | 2005-07-25 | 2007-03-29 | Merck & Co., Inc. | Dodecylsulfate salt of a dipeptidyl peptidase-iv inhibitor |
WO2008000418A2 (en) | 2006-06-27 | 2008-01-03 | Sandoz Ag | New method for salt preparation |
WO2009085990A2 (en) | 2007-12-20 | 2009-07-09 | Dr. Reddy's Laboratories Limited | Processes for the preparation of sitagliptin and pharmaceutically acceptable salts thereof |
WO2010000469A2 (en) | 2008-07-03 | 2010-01-07 | Ratiopharm Gmbh | Crystalline salts of sitagliptin |
WO2010012781A2 (en) | 2008-07-29 | 2010-02-04 | Medichem, S.A. | New crystalline salt forms of a 5,6,7,8-tetrahydro-1,2,4- triazolo[4,3-a]pyrazine derivative |
WO2010032264A2 (en) | 2008-08-27 | 2010-03-25 | Cadila Healthcare Limited | Improved process for preparation of (2r)-4-oxo-4-[3- (trifluoromethyl)-5,6-dihydro [1,2,4]-triazolo[4,3-a]pyrazin- 7(8h)-yl]-l-(2,4,5-trifluorophenyl)butan-2-amine & new impurities in preparation thereof |
WO2010092090A2 (en) | 2009-02-11 | 2010-08-19 | Lek Pharmaceuticals D.D. | Novel salts of sitagliptin |
WO2010117738A2 (en) | 2009-03-30 | 2010-10-14 | Teva Pharmaceutical Industries Ltd. | Solid state forms of sitagliptin salts |
WO2012007455A1 (en) | 2010-07-13 | 2012-01-19 | Chemo Iberica, S.A. | Process for the preparation of organic salts |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3174901A (en) * | 1963-01-31 | 1965-03-23 | Jan Marcel Didier Aron Samuel | Process for the oral treatment of diabetes |
JP5069678B2 (en) * | 2005-05-25 | 2012-11-07 | メルク・シャープ・エンド・ドーム・コーポレイション | Aminocyclohexane as a dipeptidyl peptidase IV inhibitor for the treatment or prevention of diabetes |
US20090156579A1 (en) * | 2005-10-25 | 2009-06-18 | Hasegawa Philip A | Combination of a Dipeptidyl Peptidase-4 Inhibitor and an Anti-Hypertensive Agent for the Treatment of Diabetes and Hypertension |
TW200833695A (en) * | 2006-10-12 | 2008-08-16 | Xenon Pharmaceuticals Inc | Use of spiro-oxindole compounds as therapeutic agents |
WO2008046046A1 (en) * | 2006-10-12 | 2008-04-17 | Xenon Pharmaceuticals Inc. | Tricyclic spiro-oxindole derivatives and their uses as therapeutic agents |
EP2019113A1 (en) | 2007-07-26 | 2009-01-28 | Anadys Pharmaceuticals, Inc. | New Crystalline Salts of 5-Amino-3-(2',3'-di-O-acetyl-beta-D-ribofuranosyl)-3H-thiazolo[4,5-d]pyrimidin-2-one |
US8263807B2 (en) * | 2007-08-09 | 2012-09-11 | Rensselaer Polytechnic Institute | Quaternary opioid carboxamides |
FR2933692B1 (en) | 2008-07-10 | 2022-12-02 | Univ Nancy 1 Henri Poincare | NEW COMPOUNDS, THEIR USE AS MEDICINES, AND METHOD FOR PREPARING THEM |
ES2603215T3 (en) * | 2008-12-31 | 2017-02-24 | Chiral Quest, Inc. | Process and intermediate products for the preparation of N-acylated-4-aryl beta-amino acid derivatives |
WO2013001457A1 (en) | 2011-06-30 | 2013-01-03 | Ranbaxy Laboratories Limited | Novel salts of sitagliptin |
-
2012
- 2012-03-02 CN CN201510112504.7A patent/CN104788456A/en active Pending
- 2012-03-02 DK DK12766329.2T patent/DK2681220T3/en active
- 2012-03-02 ES ES12766329.2T patent/ES2548269T3/en active Active
- 2012-03-02 BR BR112013022504A patent/BR112013022504A8/en not_active IP Right Cessation
- 2012-03-02 EP EP14196602.8A patent/EP2899194A1/en not_active Withdrawn
- 2012-03-02 WO PCT/IN2012/000148 patent/WO2012147092A2/en active Application Filing
- 2012-03-02 US US14/002,541 patent/US9108972B2/en not_active Expired - Fee Related
- 2012-03-02 EP EP12766329.2A patent/EP2681220B1/en not_active Not-in-force
- 2012-03-02 AU AU2012247127A patent/AU2012247127B2/en not_active Expired - Fee Related
- 2012-03-02 KR KR1020137026089A patent/KR20130132631A/en not_active Application Discontinuation
- 2012-03-02 CN CN2012800168764A patent/CN103476778A/en active Pending
- 2012-03-02 JP JP2013555995A patent/JP2014510071A/en active Pending
- 2012-03-02 MX MX2013010027A patent/MX2013010027A/en not_active Application Discontinuation
- 2012-03-02 EP EP20140196352 patent/EP2860180A1/en not_active Withdrawn
- 2012-03-02 SG SG10201405403QA patent/SG10201405403QA/en unknown
- 2012-03-02 EP EP14171186.1A patent/EP2789616A1/en not_active Withdrawn
- 2012-03-02 SG SG2013064886A patent/SG192973A1/en unknown
-
2015
- 2015-07-08 PH PH12015501536A patent/PH12015501536A1/en unknown
Patent Citations (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003004498A1 (en) | 2001-07-06 | 2003-01-16 | Merck & Co., Inc. | Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
US6699871B2 (en) | 2001-07-06 | 2004-03-02 | Merck & Co., Inc. | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
WO2005003135A1 (en) | 2003-06-24 | 2005-01-13 | Merck & Co., Inc. | Phosphoric acid salt of a dipeptidyl peptidase-iv inhibitor |
WO2005020920A2 (en) | 2003-09-02 | 2005-03-10 | Merck & Co., Inc. | Novel crystalline forms of a phosphoric acid salt of a dipeptidyl peptidase-iv inhibitor |
WO2005030127A2 (en) | 2003-09-23 | 2005-04-07 | Merck & Co., Inc. | Novel crystalline form of a phosphoric acid salt of a dipeptidyl peptidase-iv inhibitor |
WO2005072530A1 (en) | 2004-01-16 | 2005-08-11 | Merck & Co., Inc. | Novel crystalline salts of a dipeptidyl peptidase-iv inhibitor |
WO2006033848A1 (en) | 2004-09-15 | 2006-03-30 | Merck & Co., Inc. | Amorphous form of a phosphoric acid salt of a dipeptidyl peptidase-iv inhibitor |
WO2007035198A2 (en) | 2005-07-25 | 2007-03-29 | Merck & Co., Inc. | Dodecylsulfate salt of a dipeptidyl peptidase-iv inhibitor |
WO2008000418A2 (en) | 2006-06-27 | 2008-01-03 | Sandoz Ag | New method for salt preparation |
WO2009085990A2 (en) | 2007-12-20 | 2009-07-09 | Dr. Reddy's Laboratories Limited | Processes for the preparation of sitagliptin and pharmaceutically acceptable salts thereof |
WO2010000469A2 (en) | 2008-07-03 | 2010-01-07 | Ratiopharm Gmbh | Crystalline salts of sitagliptin |
WO2010012781A2 (en) | 2008-07-29 | 2010-02-04 | Medichem, S.A. | New crystalline salt forms of a 5,6,7,8-tetrahydro-1,2,4- triazolo[4,3-a]pyrazine derivative |
WO2010032264A2 (en) | 2008-08-27 | 2010-03-25 | Cadila Healthcare Limited | Improved process for preparation of (2r)-4-oxo-4-[3- (trifluoromethyl)-5,6-dihydro [1,2,4]-triazolo[4,3-a]pyrazin- 7(8h)-yl]-l-(2,4,5-trifluorophenyl)butan-2-amine & new impurities in preparation thereof |
WO2010092090A2 (en) | 2009-02-11 | 2010-08-19 | Lek Pharmaceuticals D.D. | Novel salts of sitagliptin |
WO2010117738A2 (en) | 2009-03-30 | 2010-10-14 | Teva Pharmaceutical Industries Ltd. | Solid state forms of sitagliptin salts |
WO2012007455A1 (en) | 2010-07-13 | 2012-01-19 | Chemo Iberica, S.A. | Process for the preparation of organic salts |
Non-Patent Citations (1)
Title |
---|
D. KIM ET AL., J. MED. CHEM., vol. 48, 2005, pages 141 - 15 |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013084210A1 (en) * | 2011-12-08 | 2013-06-13 | Ranbaxy Laboratories Limited | Amorphous form of sitagliptin salts |
ES2690866A1 (en) * | 2016-12-08 | 2018-11-22 | Alparis, S.A. De C.V. | NEW SOLID FORMS OF SITAGLIPTINE (Machine-translation by Google Translate, not legally binding) |
US10301316B2 (en) | 2016-12-08 | 2019-05-28 | Alparis, S.A. De C.V. | Solid forms of sitagliptin |
WO2022058044A1 (en) | 2020-09-15 | 2022-03-24 | Pharmathen S.A. | Solid dosage form comprising sitagliptin and method of preparation thereof |
WO2022228735A1 (en) | 2021-04-27 | 2022-11-03 | Pharmathen S.A. | Pharmaceutical composition comprising a combination of sitagliptin and metformin and method of preparation thereof |
WO2023139276A1 (en) | 2022-01-24 | 2023-07-27 | Zaklady Farmaceutyczne Polpharma S.A. | Process for preparing crystalline sitagliptin hydrochloride monohydrate |
Also Published As
Publication number | Publication date |
---|---|
BR112013022504A8 (en) | 2018-01-23 |
AU2012247127B2 (en) | 2016-01-28 |
AU2012247127A1 (en) | 2013-10-03 |
DK2681220T3 (en) | 2015-11-30 |
KR20130132631A (en) | 2013-12-04 |
EP2681220A2 (en) | 2014-01-08 |
ES2548269T3 (en) | 2015-10-15 |
EP2860180A1 (en) | 2015-04-15 |
WO2012147092A3 (en) | 2013-03-14 |
BR112013022504A2 (en) | 2016-07-19 |
EP2681220B1 (en) | 2015-08-19 |
JP2014510071A (en) | 2014-04-24 |
US20140051856A1 (en) | 2014-02-20 |
EP2899194A1 (en) | 2015-07-29 |
US9108972B2 (en) | 2015-08-18 |
CN104788456A (en) | 2015-07-22 |
CN103476778A (en) | 2013-12-25 |
SG192973A1 (en) | 2013-09-30 |
PH12015501536A1 (en) | 2015-09-21 |
SG10201405403QA (en) | 2014-11-27 |
EP2789616A1 (en) | 2014-10-15 |
MX2013010027A (en) | 2014-02-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109563099B (en) | Crystal form of compound, preparation and application thereof | |
US8309724B2 (en) | Processes for the preparation of sitagliptin and pharmaceutically acceptable salts thereof | |
WO2010023561A1 (en) | Process for preparing varenicline, varenicline intermediates, and pharmaceutically acceptable salts thereof | |
US9603846B2 (en) | Process for the preparation of apixaban | |
WO2012025944A2 (en) | Sitagliptin, salts and polymorphs thereof | |
WO2012147092A2 (en) | Novel salts of dpp-iv inhibitor | |
US20100041885A1 (en) | Crystalline forms of sitagliptin phosphate | |
US20140350023A1 (en) | Amorphous form of sitagliptin salts | |
CZ300692B6 (en) | Solifenacin preparation process | |
EP2489666A2 (en) | Chemically and chirally pure solifenacin base and its salts | |
US20150051213A1 (en) | Novel salts of sitagliptin | |
KR101557832B1 (en) | Stable crystalline salt of (r)-3-fluoropheny-3,4,5-trifluorobenzylcarbamic acid 1-azabicyclo[2.2.2]oct-3-yl ester | |
AU2015275291A1 (en) | Novel salts of DPP-IV inhibitor | |
WO2014006569A2 (en) | Saxagliptin salts |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2013/010027 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref document number: 2013555995 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1301004868 Country of ref document: TH |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012766329 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 20137026089 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2012247127 Country of ref document: AU Date of ref document: 20120302 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14002541 Country of ref document: US |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112013022504 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112013022504 Country of ref document: BR Kind code of ref document: A2 Effective date: 20130903 |